Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.30 |
| ▸ | ALPL | P05186 | 1/20 | 0.30 |
| ▸ | ALPI | P09923 | 1/20 | 0.30 |
| ▸ | ALPG | P10696 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3062079 | 1.00 | CTSB (0.46) | CTSBADRB3ADRA2BADRA2CCTSS | |
| SCHEMBL15509635 | 1.00 | CTSB (0.46) | CTSBADRB3ADRA2BADRA2CCTSS | |
| SCHEMBL3061921 | 1.00 | CTSB (0.46) | CTSBADRB3ADRA2BADRA2CCTSS | |
| SCHEMBL3061915 | 1.00 | CTSB (0.46) | CTSBADRB3ADRA2BADRA2CCTSS | |
| SCHEMBL15643297 | 1.00 | CTSB (0.46) | CTSBADRB3ADRA2BADRA2CCTSS | |
| SCHEMBL2800104 | 0.93 | CTSB (0.42) | CTSBADRB3ADRA2BADRA2CCTSS | |
| SCHEMBL2800106 | 0.93 | CTSB (0.42) | CTSBADRB3ADRA2BADRA2CCTSS | |
| SCHEMBL2157642 | 0.91 | CTSB (0.46) | CTSBADRB3ADRA2BADRA2CCTSS | |
| SCHEMBL3068073 | 0.91 | CTSB (0.46) | CTSBADRB3ADRA2BADRA2CCTSS | |
| SCHEMBL2798638 | 0.91 | CTSB (0.41) | CTSBADRB3ADRA2BADRA2CCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8420596-B2 | Macrocyclic hepatitis C serine protease inhibitors | ABBOTT LABORATORIES (US) | 2013-04-16 | — | — | US | disclosed |
| US-20100144608-A1 | Macrocyclic hepatitis C serine protease inhibitors | ABBVIE INC. | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144608-A1 | Macrocyclic hepatitis C serine protease inhibitors | TMPRSS15, PRSS1, SPINT2 | CTSB 65/4885ADRB3 3933/4885ADRA2B 4558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.